Iylon Precision Oncology Appoints Dr. Razelle Kurzrock as Chief Medical Advisor

Precision oncology pioneer Dr. Razelle Kurzrock joins Iylon to help advance expert-informed, individualized cancer discussions for physicians and patients.


Dr. Razelle "Ray" Kurzrock, M.D.,

PROVIDENCE, RI, UNITED STATES, September 14, 2026 /EINPresswire.com/ -- Iylon Appoints Dr. Razelle Kurzrock as Chief Medical Advisor

Renowned precision oncology pioneer will help guide Iylon's mission to deliver expert, individualized cancer-treatment discussions

Iylon Precision Oncology, LLC, a precision oncology company dedicated to helping treating physicians and their patients to navigate complex cancer-care decisions, today announced the appointment of Razelle "Ray" Kurzrock, M.D., as its Chief Medical Advisor.

Dr. Kurzrock is an internationally recognized leader in precision oncology, early-phase clinical trials, and individualized cancer therapy. She is currently Professor of Medicine, Director, Center for Precision Oncology and Rare Cancers at the Medical College of Wisconsin Cancer Center and Linda T. and John A. Mellowes Endowed Chair of Precision Oncology, as well as CMO for the Worldwide Innovative Network for Precision Medicine. In this role at Iylon, she will provide strategic clinical guidance to Iylon and help advance its work in delivering evidence-based, personalized recommendations for treating oncology teams and their patients.

"Iylon was founded on the belief that every oncologist and their patient deserves access to thoughtful, individualized cancer guidance informed by the most current science and clinical expertise," said John A. Tarantino, Chief Executive Officer of Iylon. "Dr. Kurzrock has been a defining force in precision oncology. Her leadership, clinical insight, and commitment to patients are invaluable as Iylon expands its ability to support physicians and their patients confronting difficult treatment decisions."

> Cancer care is increasingly complex; physicians & their patients need practical, scientifically rigorous guidance that reflects the molecular features of the tumor & the individual needs of patients."
>
> *Razelle "Ray" Kurzrock, M.D.,*

Dr. Kurzrock has devoted her career to translating scientific discoveries into new treatment opportunities for patients with advanced and difficult-to-treat cancers. She has led numerous early-phase clinical trials and has been a prominent advocate for matching treatment strategies to each patient's tumor biology, molecular profile, and clinical circumstances.

"I am pleased to join Iylon at an important moment for precision oncology," said Dr. Kurzrock. "Cancer care is increasingly complex, and physicians and their patients need practical, scientifically rigorous guidance that reflects both the molecular features of the tumor and the individual needs of the patient. Iylon's model of independent, multidisciplinary discussion and education has the potential to help make personalized cancer care more accessible and actionable."

As Chief Medical Advisor, Dr. Kurzrock will contribute to Iylon's clinical review educational framework, advisor network, and the strategic development of learning services designed to complement the care provided by a patient's treating oncology team.

"Dr. Kurzrock's appointment further strengthens Iylon's commitment to bringing leading clinical and scientific expertise directly into the decision-making process," said Sendurai A. Mani, Ph.D., Co-Founder and Chief Scientific Officer of Iylon. "Her pioneering work has helped shape the field's understanding of how precision medicine can improve care for patients with cancer. We are honored to welcome her to Iylon."

Iylon works with a growing network of oncology experts to provide personalized education and discussion that can help clinicians and their patients better understand available options and facilitate informed deliberations about care.

About Iylon: Iylon is a precision oncology company focused on delivering individualized, expert-informed cancer discussion for treating physicians and their patients. Through independent multidisciplinary expertise, Iylon helps clarify complex cancer-care by integrating medical history, tumor biology, molecular data, current evidence, and relevant clinical opportunities.

Dr. Arun kumar
Iylon Precision Oncology
4014001430
media@iylon.com
Visit us on social media:
LinkedIn
Instagram

Facebook
YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/941957836

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.